Does CYP2C19 loss-of-function allele carrier status increase the risk of stroke and composite vascular events in patients with ischemic stroke or TIA treated with clopidogrel?
Patients with ischemic stroke or transient ischemic attack (TIA) treated with clopidogrel
Clopidogrel therapy in carriers of CYP2C19 loss-of-function alleles
Clopidogrel therapy in noncarriers of CYP2C19 loss-of-function alleles
Stroke and composite vascular eventscomposite
CYP2C19 loss-of-function allele carriers have reduced clopidogrel efficacy, leading to a higher risk of recurrent stroke and vascular events after an ischemic stroke or TIA.
Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events than noncarriers among patients with ischemic stroke or TIA treated with clopidogrel.
Building similarity graph...
Analyzing shared references across papers
Loading...
Pan et al. (Thu,) studied this question.
synapsesocial.com/papers/69da216d0d540cafc58386b0 — DOI: https://doi.org/10.1161/circulationaha.116.024913
Yuesong Pan
Vascular Medicine
Weiqi Chen
Vascular Medicine
Yun Xu
Tongji University
Circulation
Wanfang Data (China)
Building similarity graph...
Analyzing shared references across papers
Loading...